Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
Total Valuation
Caris Life Sciences, Inc. has a market cap or net worth of $9.23B. The enterprise value is $7.21B.
Market Cap$9.23B
Enterprise Value$7.21B
Share Statistics
Caris Life Sciences, Inc. has 281,224,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding281,224,120
Owned by Insiders70.64%
Owned by Institutions25.73%
Financial Efficiency
Caris Life Sciences, Inc.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is -105.17%.
Return on Equity (ROE)0.11
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-105.17%
Return on Capital Employed (ROCE)-1.44
Revenue Per Employee233.05K
Profits Per Employee-159.35K
Employee Count1,769
Asset Turnover1.20
Inventory Turnover5.90
Valuation Ratios
The current PE Ratio of Caris Life Sciences, Inc. is ―. Caris Life Sciences, Inc.’s PEG ratio is -0.52.
PE Ratio―
PS Ratio17.30
PB Ratio-2.85
Price to Fair Value-2.85
Price to FCF-28.11
Price to Operating Cash Flow-88.92
PEG Ratio-0.52
Income Statement
In the last 12 months, Caris Life Sciences, Inc. had revenue of 412.26M and earned -281.89M in profits. Earnings per share was -2.70.
Revenue412.26M
Gross Profit178.78M
Operating Income-257.12M
Pretax Income-281.89M
Net Income-281.89M
EBITDA-182.95M
Earnings Per Share (EPS)-2.70
Cash Flow
In the last 12 months, operating cash flow was -24.05M and capital expenditures -4.08M, giving a free cash flow of -28.13M billion.
Operating Cash Flow-24.05M
Free Cash Flow-28.13M
Free Cash Flow per Share-0.10
Dividends & Yields
Caris Life Sciences, Inc. pays an annual dividend of $0.3, resulting in a dividend yield of ―
Dividend Per Share$0.3
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.28
52-Week Price Change15.89%
50-Day Moving Average33.20
200-Day Moving Average―
Relative Strength Index (RSI)46.79
Average Volume (3m)676.55K
Important Dates
Caris Life Sciences, Inc. upcoming earnings date is Aug 12, 2025, After Close (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateAug 12, 2025
Ex-Dividend DateSep 09, 2021
Financial Position
Caris Life Sciences, Inc. as a current ratio of 1.30, with Debt / Equity ratio of 92.51%
Current Ratio1.30
Quick Ratio1.06
Debt to Market Cap0.05
Net Debt to EBITDA-1.97
Interest Coverage Ratio-5.14
Taxes
In the past 12 months, Caris Life Sciences, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Caris Life Sciences, Inc. EV to EBITDA ratio is -40.94, with an EV/FCF ratio of -29.53.
EV to Sales18.17
EV to EBITDA-40.94
EV to Free Cash Flow-29.53
EV to Operating Cash Flow-30.55
Balance Sheet
Caris Life Sciences, Inc. has $721.18M in cash and marketable securities with $418.98M in debt, giving a net cash position of $302.20M billion.
Cash & Marketable Securities$721.18M
Total Debt$418.98M
Net Cash$302.20M
Net Cash Per Share$1.07
Tangible Book Value Per Share-$9.89
Margins
Gross margin is 56.48%, with operating margin of -62.37%, and net profit margin of -68.38%.
Gross Margin56.48%
Operating Margin-62.37%
Pretax Margin-68.38%
Net Profit Margin-68.38%
EBITDA Margin-44.38%
EBIT Margin-56.24%
Analyst Forecast
The average price target for Caris Life Sciences, Inc. is $38.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$38.25
Price Target Upside21.12% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast―